Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients

This study is testing whether giving azacitidine and venetoclax (two cancer drugs) to people with AML or MDS (blood cancers) who have had a stem cell transplant and still show small signs of remaining cancer (called MRD-positive) can eliminate those residual cancer cells and prevent relapse. **You may be eligible if...** - You are between 18 and 65 years old - You have AML or MDS (diagnosed by WHO criteria) - You have had an allogeneic (donor) stem cell transplant and achieved complete remission - After transplant, sensitive tests still detect small amounts of remaining cancer cells (MRD-positive) **You may NOT be eligible if...** - Your cancer has fully relapsed after transplant - You have graft-versus-host disease that is not well-controlled - You have severe organ dysfunction Talk to your doctor to see if this trial is right for you.